Typicality: | 0.429 |
Saliency: | 0.420 |
with disease progression | 7 | other |
after platinum-containing chemotherapy | 6 | temporal |
tumor → be determined by → fda-approved test | 27 |
tumor → be detected by → fda-approved test | 13 |
negative | neutral | positive |
0.089 | 0.797 | 0.114 |
Raw frequency | 40 |
Normalized frequency | 0.420 |
Modifier score | 0.500 |
Perplexity | 110.898 |